5090 indexable Life Sciences companies headquartered in California, United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $153.4B across 2822 funded companies, including 20 unicorns.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Neuralink
Unicorn Provider of implantable brain-computer interfaces |
$680M | $5B as of 2023 |
Series E | Series E May 2026 | 197 | 2016 | ↑ Active |
| 2 |
Quince Therapeutics
Developer of therapeutics for orthopedic diseases |
$420.1M | — | Public | Post IPO May 2026 | 21 | 2012 | ↑ Active |
| 3 |
Imperative Care
Provider of access catheters for cardiovascular diagnosis and treatment |
$496M | — | Series E | Series E Mar 2026 | 90 | 2015 | ↑ Active |
| 4 |
GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer |
$2B | — | Public | Post IPO Oct 2025 | 491 | 2016 | ↑ Active |
| 5 |
Senti Bio
Developer of cell and gene therapies for patients living with incurable diseases |
$158M | — | Public | Post IPO May 2026 | 122 | 2016 | ↑ Active |
| 6 |
Bioventrix
Ventricle reshaping device |
$181.4M | — | Series E | Series E Apr 2026 | 20 | 2003 | ↑ Active |
| 7 |
Terremoto
Developer of small-molecule therapeutics for cancer treatment |
$250M | — | Series C | Series C Apr 2026 | 35 | 2021 | ↑ Active |
| 8 |
Cala Health
Developer of a wearable non-invasive neuromodulation device |
$157.1M | — | Series D | Conventional Debt Apr 2026 | 50 | 2013 | ↑ Active |
| 9 |
Iambic Therapeutics
Provider of AI-driven drug discovery platform for the treatment of cancer |
$206.2M | — | Series C | Series C Apr 2026 | 50 | 2019 | ↑ Active |
| 10 |
Science
Unicorn Provider of online science magazine |
$360M | — | Series C | Series C Feb 2026 | 76 | 2021 | ↑ Active |
| 11 |
Evommune
Developer of therapeutic options for chronic inflammatory disorders |
$268M | — | Public | Post IPO Feb 2026 | 33 | 2020 | ↑ Active |
| 12 |
Mirador
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases |
$480M | — | Series B | Series B Jan 2026 | — | 2023 | ↑ Active |
| 13 |
Cellares
Manufacturer of a medical device for cell-based therapy |
$355M | — | Series D | Series D Jan 2026 | 154 | 2019 | ↑ Active |
| 14 |
Ray Therapeutics
Developer of therapeutics for degenerative retinal diseases |
$106M | — | Series B | Series B Apr 2026 | 10 | 2021 | ↑ Active |
| 15 |
Alto Neuroscience
AI-driven drug discovery platform for neurological diseases based on patients biomarkers |
$144.7M | — | Public | Post IPO Mar 2026 | 34 | 2019 | ↑ Active |
| 16 |
Guardant Health
Developer of digital sequencing technology for cancer detection |
$557.5M | — | Public | Post IPO Nov 2025 | 1,351 | 2012 | ↑ Active |
| 17 |
Summit
Developer of therapeutics for oncology and rare diseases |
$713M | — | Public | Post IPO Oct 2025 | 99 | 2003 | ↑ Active |
| 18 |
Adela
Developer of a platform for detection of cancer |
$108.5M | — | Series A | Series A Apr 2026 | 62 | 2021 | ↑ Active |
| 19 |
Endovascular Engineering
Provider of mechanical thrombectomy technologies to treat venous thromboembolism |
$122.3M | — | Series C | Series C Apr 2026 | 19 | 2019 | ↑ Active |
| 20 |
Candid Therapeutics
Developer of therapeutics for autoimmune diseases |
$206.2M | — | Acquired | Series E Mar 2026 | — | 2024 | ↑ Active |
| 21 |
NovaBay Pharmaceuticals
Developer of eye care and wound care products |
$219.5M | — | Public | Post IPO Jan 2026 | 33 | 2000 | ↑ Active |
| 22 |
ClearNote Health
Developer of non-invasive cancer detection methods |
$70M | — | Series D | Series D May 2026 | 45 | 2016 | ↑ Active |
| 23 |
Neomorph
Developer of therapeutic solutions for the treatment of multiple diseases based on protein degradation technology |
$109M | — | Series B | Series B Apr 2026 | 54 | 2003 | ↑ Active |
| 24 |
Alamar Biosciences
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels |
$250M | — | Public | Series C Jan 2026 | 83 | 2018 | ↑ Active |
| 25 |
Orca Bio
Unicorn Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders |
$300M | $1B as of 2020 |
Series F | Series F Jan 2026 | 66 | 2016 | ↑ Active |
| 26 |
Angitia
Developer of drugs for muscle, bone, and joint diseases |
$156M | — | Series D | Series D Feb 2026 | — | 2018 | ↑ Active |
| 27 |
Calyxo
Standalone nephrology hospital |
$82.7M | — | Series F | Series F Apr 2026 | 48 | 2016 | ↑ Active |
| 28 |
TEMPEST THERAPEUTICS
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit |
$88.2M | — | Public | Post IPO Mar 2026 | 19 | 2011 | ↑ Active |
| 29 |
Merge Labs
Developer of brain-computer interfaces to maximize human ability, agency, experience |
$250M | — | Seed | Seed Jan 2026 | — | 2025 | ↑ Active |
| 30 |
Rakuten Medical
Developer of a photoimmunotherapy platform for treating cancer |
$874.3M | — | Series F | Series F Jul 2025 | 110 | 2013 | ↑ Active |
| 31 |
BrightInsight
Provider of digital health solutions for clinical trials |
$166.1M | — | Series C | Series C Jan 2026 | 165 | 2017 | ↑ Active |
| 32 |
LTZ Therapeutics
Developer of immunotherapies to treat cancer and other diseases |
$47M | — | Series B | Series B May 2026 | 23 | 2021 | ↑ Active |
| 33 |
Cartography Biosciences
Provider of a platform to discover immunotherapeutics |
$57M | — | Series B | Series B May 2026 | 10 | 2020 | ↑ Active |
| 34 |
Emboline
Developer of an aortic embolic protection device |
$81.9M | — | Series D | Series D Mar 2026 | 13 | 2011 | ↑ Active |
| 35 |
Route 92 Medical
Developer of next-generation products for neurointerventional procedures |
$137.7M | — | Series F | Series F Jan 2026 | 51 | 2015 | ↑ Active |
| 36 |
Signos
Provider of a wearable device for blood glucose pattern monitoring |
$37M | — | Series B | Series B May 2026 | 30 | 2020 | ↑ Active |
| 37 |
Aureka Biotechnologies
Biotech company digitizing therapeutic discovery to manage human health |
$58M | — | Series A | Series A Apr 2026 | — | 2023 | ↑ Active |
| 38 |
AN2 Therapeutics
Developer of drugs for treating infectious disease |
$92M | — | Public | Post IPO Mar 2026 | 35 | 2017 | ↑ Active |
| 39 |
Chai Discovery
Unicorn Developer of artificial intelligence models for de novo molecular design |
$230M | — | Series B | Series B Dec 2025 | — | 2023 | ↑ Active |
| 40 |
ReviR Therapeutics
Developer of RNA-based therapeutics for multiple diseases |
$54M | — | Series A | Series A Apr 2026 | 29 | 2021 | ↑ Active |
| 41 |
ReCode Therapeutics
Developer of precision medicines for treating lung related diseases |
$342M | $372M as of 2021 |
Series B | Series B Sep 2025 | 105 | 2015 | ↑ Active |
| 42 |
Aspen Neuroscience
Provider of genomic-based personalised pluripotent stem cell therapy |
$224M | — | Series C | Series C Nov 2025 | 94 | 2018 | ↑ Active |
| 43 |
BlossomHill Therapeutics
Provider of the drug for the treatment of oncology and autoimmune disorders |
$259.6M | — | Series B | Series B Nov 2025 | 14 | 2020 | ↑ Active |
| 44 |
Antheia
Genetically engineered yeast cells to produce medicinal products |
$96.4M | — | Series C | Series C Jan 2026 | 50 | 2013 | ↑ Active |
| 45 |
OncoSynergy
Developer of resistance mechanism inhibitors to treat cancer |
$26.7M | — | Acquired | Series A May 2026 | 3 | 2011 | ↑ Active |
| 46 |
Triomics
Provider of clinical research and clinical trial tracking software |
$28.9M | — | Series B | Series B May 2026 | 29 | 2020 | ↑ Active |
| 47 |
Rani Therapeutics
Developer of technology for the oral delivery of large drug molecules |
$234.1M | — | Public | Post IPO Oct 2025 | 163 | 2012 | ↑ Active |
| 48 |
Kriya Therapeutics
Developer of therapeutic solutions for the treatment of diabetes |
$617.6M | — | Series D | Series D Jul 2025 | 159 | 2012 | ↑ Active |
| 49 |
Mirum Pharmaceuticals
Developer of small molecule based therapeutics to treat rare diseases |
$120M | — | Public | Post IPO Jan 2026 | 196 | 2018 | ↑ Active |
| 50 |
PrognomiQ
Developer of tests for the detection and treatment of cancer and other diseases |
$135M | — | Series D | Series D Jan 2026 | 24 | 2020 | ↑ Active |
Provider of implantable brain-computer interfaces. It offers flagship product the N1 Implant the Link which is a coin-sized device designed to decode neural signals and enable users to control digital devices using only their thoughts. It also has an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
Developer of therapeutics for orthopedic diseases. It offers a lead candidate NOV004 which is an anabolic peptide engineered to target and concentrate at the bone fracture site and also helps in spinal fusion and osteogenesis Imperfecta.
Provider of access catheters for cardiovascular diagnosis and treatment. The catheters are used in deep navigation into the blood vessels of the brain to prevent strokes. The flagship product ZOOM Aspiration System is a family of products designed to facilitate clot removal during ischemic stroke.
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
BioVentrix develops clinical solutions for treating heart failure patients. It provides PliCath HF, an epicardial catheter-based ventricular reconstruction device. Product is not commercially available.
Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.
Developer of a wearable non-invasive neuromodulation device. The company has developed a neuromodulation device that aims to provide relief of hand tremors in adults with essential tremors. It combines a watch-like device with an implantable sensor that externally stimulates peripheral nerves to reduce the same. The company has also developed a portable medical device with sensors to monitor the physical movement of
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle drive
Provider of online science magazine. They specialize in offering content in various topics such as science for patients,technologies and much more.
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases. The company’s Mirador360 precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-16.
